United Health (UNH) attracts value investors after Q3 earnings beat, but rising costs and margin pressures pose risks.

Defensive blue-chip stock UnitedHealth is on a credible path back to double-digit growth next year, but is UNH a buy right ...

Investing.com -- Deutsche Bank cut its rating on UnitedHealth Group to Hold from Buy, saying the stock’s valuation now reflects its expected earnings rebound. The brokerage lifted its price target to ...

In his opening statement, Nelson Mullins’ Michael A. Brown, representing the company, said evidence would show the talc did ...

UnitedHealth Group Incorporated UNH reported third-quarter 2025 adjusted earnings per share (EPS) of $2.92, which beat the ...

The specialty grocer, which spends millions each year on insulin for employees, accused the companies of profiting from ...

UnitedHealth Group operates a top-tier health insurer (UnitedHealthcare), pharmacy benefit manager (Optum Rx), provider (Optum Health), and health analytics franchise (Optum Insight). Historically, ...

UnitedHealth Group delivered Q3 revenue of $113.2 billion, up 12.3% year-over-year, slightly ahead of consensus estimates.

Cigna will eliminate prescription drug rebates in many of its commercial health plans in 2027, upending a practice that’s ...

Cigna Group will stop offering prescription drug rebates in many of its commercial health plans starting in 2027, Bloomberg’s ...

Cigna will remove drug rebates from 2027, replacing them with upfront discounts that could change how Americans pay for ...